Immunoassay tests are used in clinical and forensic toxicology laboratories to determine illicit drug use in biological samples. Therefore, this study aims to optimize the cutoff concentrations of DOA I Plus in the blood and compare the LC-MS/MS results. 680 authentic forensic whole blood specimens with Randox Evidence DOA I Plus array were screened for drug of abuse and confirmed by LC-MS/MS. Regarding the manufacturer recommended threshold values, 139 out of 680 authentic blood samples were positive for one or more analytes, while 541 were negative. Nearly all of the 139 positive blood samples confirmed by LC-MS/MS were true positive for one or more analytes, while 522 of the 541 negative blood samples were true negative. The overall sensitivity and the specificity were 87.8% and 99.6%, respectively. THC was considered in detail, and a receiver operator characteristic curve analysis was performed to determine the optimum cutoff for THC, as it accounts for 78% of all positive results according to the manufacturer's recommended thresholds. The optimal threshold value for THC was determined at a concentration of 23 ng/mL, while these values for other parameters were defined as recommended by the manufacturer.
免疫分析测试用于临床和法医毒理学实验室,以确定生物样本中的非法药物使用。因此,本研究旨在优化血液中DOA I Plus的截止浓度,并比较LC-MS/MS结果。使用Randox Evidence DOA I Plus阵列对680份真实的法医全血样本进行滥用药物筛选,并通过LC-MS/MS进行确认。关于制造商建议的阈值,680份真实血液样本中有139份对一种或多种分析物呈阳性,541份呈阴性。LC-MS/MS确认的139份阳性血液样本中,几乎所有的一种或多种分析物均为真阳性,541份阴性血液样本中有522份为真阴性。总的敏感性和特异性分别为87.8%和99.6%。详细考虑了四氢大麻酚,并进行了受试者-操作员特性曲线分析,以确定四氢大麻醚的最佳截止值,因为根据制造商的建议阈值,它占所有阳性结果的78%。THC的最佳阈值是在浓度为23时确定的 ng/mL,而其他参数的这些值是按照制造商的建议定义的。
{"title":"Optimization of biochip assay for illegal substances on drug abusers' whole blood: Randox Evidence vs LC-MS/MS.","authors":"Pinar Efeoglu Ozseker, Sevinc Puren Yucel, Nebile Daglioglu","doi":"10.1080/15321819.2023.2189451","DOIUrl":"10.1080/15321819.2023.2189451","url":null,"abstract":"<p><p>Immunoassay tests are used in clinical and forensic toxicology laboratories to determine illicit drug use in biological samples. Therefore, this study aims to optimize the cutoff concentrations of DOA I Plus in the blood and compare the LC-MS/MS results. 680 authentic forensic whole blood specimens with Randox Evidence DOA I Plus array were screened for drug of abuse and confirmed by LC-MS/MS. Regarding the manufacturer recommended threshold values, 139 out of 680 authentic blood samples were positive for one or more analytes, while 541 were negative. Nearly all of the 139 positive blood samples confirmed by LC-MS/MS were true positive for one or more analytes, while 522 of the 541 negative blood samples were true negative. The overall sensitivity and the specificity were 87.8% and 99.6%, respectively. THC was considered in detail, and a receiver operator characteristic curve analysis was performed to determine the optimum cutoff for THC, as it accounts for 78% of all positive results according to the manufacturer's recommended thresholds. The optimal threshold value for THC was determined at a concentration of 23 ng/mL, while these values for other parameters were defined as recommended by the manufacturer.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 4","pages":"313-325"},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9842012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.1080/15321819.2023.2224865
Asmaa El-Shershaby, Nahla Hussein, Esraa Ali, Amr El-Hakim, Ashraf Tabll, Mohamed Shaheen, Ibrahim Ali, Mahmoud Elshall, Yasser Shahein
Several diagnostic measures have been employed to precisely detect the SARS-CoV-2 viral infection using viral antigens, nucleic acids, and other serological approaches. The sensitivity and specificity of the serological tests remain a challenging need. Here, we describe the detection of human anti-SARS-CoV-2 IgG and IgM antibodies qualitatively through two optimized in-house ELISA and lateral flow immunoassay. Both approaches are based on the prokaryotic expression of 50 kDa SARS-CoV-2 recombinant nucleocapsid protein. This SARS-CoV-2rN-6×His was used either to coat ELISA plates or to be conjugated to gold nanoparticles followed by colorimetric detection of bound human IgG or IgM. In the LFA, we show the optimization of nanoparticle size, protein-binding capacity, membrane treatment, and finally testing the potential capacity of using either the optimized ELISA or LFA in detecting antibodies raised against viral infection. Assessment of both methods was carried out using human sera-positive and negative SARS-CoV-2 antibodies. The ELISA and LFA tests showed 86%, 96.5% sensitivity, 92%, 93.75% specificity, 97%, 98.2% PPV, and 64%, 88.2% NPV, respectively. In conclusion, both approaches were able to successfully detect human antibodies against SARS-CoV-2 nucleocapsid protein. The importance of both protocols cannot be overstated in the detection and diagnosis of viral infections, especially in developing countries.
{"title":"Comparative assessment of homemade ELISA and lateral flow assay (LFA)in the rapid, specific and sensitive detection of SARS-CoV-2 anti-nucleocapsid protein in sera of Egyptian patients.","authors":"Asmaa El-Shershaby, Nahla Hussein, Esraa Ali, Amr El-Hakim, Ashraf Tabll, Mohamed Shaheen, Ibrahim Ali, Mahmoud Elshall, Yasser Shahein","doi":"10.1080/15321819.2023.2224865","DOIUrl":"https://doi.org/10.1080/15321819.2023.2224865","url":null,"abstract":"<p><p>Several diagnostic measures have been employed to precisely detect the SARS-CoV-2 viral infection using viral antigens, nucleic acids, and other serological approaches. The sensitivity and specificity of the serological tests remain a challenging need. Here, we describe the detection of human anti-SARS-CoV-2 IgG and IgM antibodies qualitatively through two optimized in-house ELISA and lateral flow immunoassay. Both approaches are based on the prokaryotic expression of 50 kDa SARS-CoV-2 recombinant nucleocapsid protein. This SARS-CoV-2rN-6×His was used either to coat ELISA plates or to be conjugated to gold nanoparticles followed by colorimetric detection of bound human IgG or IgM. In the LFA, we show the optimization of nanoparticle size, protein-binding capacity, membrane treatment, and finally testing the potential capacity of using either the optimized ELISA or LFA in detecting antibodies raised against viral infection. Assessment of both methods was carried out using human sera-positive and negative SARS-CoV-2 antibodies. The ELISA and LFA tests showed 86%, 96.5% sensitivity, 92%, 93.75% specificity, 97%, 98.2% PPV, and 64%, 88.2% NPV, respectively. In conclusion, both approaches were able to successfully detect human antibodies against SARS-CoV-2 nucleocapsid protein. The importance of both protocols cannot be overstated in the detection and diagnosis of viral infections, especially in developing countries.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 4","pages":"338-359"},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10213509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-04DOI: 10.1080/15321819.2022.2138718
Mohammad Mohammadi, Mohammad Zangooei, Ebrahim Abbasi, Saeed Ebrahimi Fana, Mahdi Aminian
Tetanus is an acute and often fatal infectious disease caused by Clostridium tetani. Tetanus toxin (TT) is responsible for spastic paralysis observed in tetanus. Anti-tetanus antibodies obtained from horses and humans are the most antitoxins used for tetanus treatment, although some clinical side effects and disadvantages have been reported in their application. The aim of this study is the production of anti-TT IgY and evaluation of its protective effects in a mouse model. Anti-TT IgY was purified from the egg yolk using PEG6000 precipitation and water dilution methods, and its purity was verified by SDS-PAGE. Finally, the potency of purified anti-TT IgY in neutralizing the lethal effects of TT was studied in vivo using a mouse model. PEG6000 precipitation method had better results. Animal studies showed that the purified IgY neutralized the toxic effects of 100 MLD of TT and multiple intravenous-dose injections of anti-TT IgY also had a continuous effect of TT neutralization. The purified anti-TT IgY was effective in neutralizing the lethal activity of TT in a mouse model. Our results suggested that IgY could be an alternative therapeutic source for the management of tetanus in the future.Abbreviations Anti-TT, Anti-tetanus toxin; ELISA, Enzyme-linked immunosorbent assay; IgY, Immunoglobulin Y; MLD, Minimum lethal dose; PBS, Phosphate buffer solution; PEG, Polyethylene glycol; SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis; TIG, Tetanus immune globulin; TT, Tetanus toxin; WD, Water dilution; RT, Room temperature.
{"title":"Production of anti-tetanus toxin IgY and study of its protective effects in a mouse model.","authors":"Mohammad Mohammadi, Mohammad Zangooei, Ebrahim Abbasi, Saeed Ebrahimi Fana, Mahdi Aminian","doi":"10.1080/15321819.2022.2138718","DOIUrl":"https://doi.org/10.1080/15321819.2022.2138718","url":null,"abstract":"<p><p>Tetanus is an acute and often fatal infectious disease caused by <i>Clostridium tetani</i>. Tetanus toxin (TT) is responsible for spastic paralysis observed in tetanus. Anti-tetanus antibodies obtained from horses and humans are the most antitoxins used for tetanus treatment, although some clinical side effects and disadvantages have been reported in their application. The aim of this study is the production of anti-TT IgY and evaluation of its protective effects in a mouse model. Anti-TT IgY was purified from the egg yolk using PEG6000 precipitation and water dilution methods, and its purity was verified by SDS-PAGE. Finally, the potency of purified anti-TT IgY in neutralizing the lethal effects of TT was studied <i>in vivo</i> using a mouse model. PEG6000 precipitation method had better results. Animal studies showed that the purified IgY neutralized the toxic effects of 100 MLD of TT and multiple intravenous-dose injections of anti-TT IgY also had a continuous effect of TT neutralization. The purified anti-TT IgY was effective in neutralizing the lethal activity of TT in a mouse model. Our results suggested that IgY could be an alternative therapeutic source for the management of tetanus in the future.<b>Abbreviations</b> Anti-TT, Anti-tetanus toxin; ELISA, Enzyme-linked immunosorbent assay; IgY, Immunoglobulin Y; MLD, Minimum lethal dose; PBS, Phosphate buffer solution; PEG, Polyethylene glycol; SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis; TIG, Tetanus immune globulin; TT, Tetanus toxin; WD, Water dilution; RT, Room temperature.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"283-295"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9259788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-04DOI: 10.1080/15321819.2022.2159765
Hasan Farajipour, Saeed Sadr, Hamid Reza Matin, Michael Aschner, Zatollah Asemi, Zarrin Banikazemi, Hamed Mirzaei, Mohsen Taghizadeh
Probiotics positively influence age-related macular degeneration (ARMD) given their propensity to attenuate oxidative and inflammatory stress. We addressed the impact of probiotics on metabolic profiles, clinical indices, inflammatory and oxidative stress parameters in ARMD patients. We performed a randomized, double-blind, placebo-controlled trial analyzing 57 subjects with ARMD aged between 50 and 85 years. Subjects were randomized into two groups, and received daily for 8 weeks either probiotic capsule or placebo. Fasting blood samples were obtained at baseline and after the 8-week intervention for the determination of metabolic profiles and oxidative stress biomarkers. After the 8-week intervention, compared with the placebo, probiotic supplementation significantly increased means HDL-cholesterol (Probiotic group: +3.86±4.42 vs. Placebo group: -0.55±4.93 mg/dL, P = .001), plasma total antioxidant capacity (TAC) (Probiotic group: +77.43±168.30 vs. Placebo group: -23.12±169.22 mmol/L, P = .02) and significantly decreased malondialdehyde (MDA) levels (Probiotic group: -0.18±0.46 vs. Placebo group: +0.18±0.25 µmol/L, P = .001). There was no significant effect of probiotic administration on other metabolic profiles and clinical symptoms. Overall, an eight-week probiotic administration among ARMD patients had beneficial effects on TAC, MDA and HDL-cholesterol levels; however, it did not affect clinical signs and other metabolic profiles.
益生菌对年龄相关性黄斑变性(ARMD)有积极影响,因为它们有减轻氧化和炎症应激的倾向。我们研究了益生菌对ARMD患者代谢谱、临床指标、炎症和氧化应激参数的影响。我们进行了一项随机、双盲、安慰剂对照试验,分析了57名年龄在50至85岁之间的ARMD患者。受试者被随机分为两组,每天服用益生菌胶囊或安慰剂,持续8周。在基线和干预8周后获得空腹血液样本,以确定代谢谱和氧化应激生物标志物。干预8周后,与安慰剂组相比,补充益生菌显著提高了hdl -胆固醇(益生菌组:+3.86±4.42 vs安慰剂组:-0.55±4.93 mg/dL, P = 0.001),血浆总抗氧化能力(TAC)(益生菌组:+77.43±168.30 vs安慰剂组:-23.12±169.22 mmol/L, P = 0.02),显著降低了丙二醛(MDA)水平(益生菌组:-0.18±0.46 vs安慰剂组:+0.18±0.25µmol/L, P = 0.001)。益生菌给药对其他代谢特征和临床症状没有显著影响。总体而言,ARMD患者服用8周益生菌对TAC、MDA和hdl -胆固醇水平有有益影响;然而,它不影响临床症状和其他代谢特征。
{"title":"Therapeutic effect of probiotics on metabolic indices and clinical signs in age-related macular degeneration.","authors":"Hasan Farajipour, Saeed Sadr, Hamid Reza Matin, Michael Aschner, Zatollah Asemi, Zarrin Banikazemi, Hamed Mirzaei, Mohsen Taghizadeh","doi":"10.1080/15321819.2022.2159765","DOIUrl":"https://doi.org/10.1080/15321819.2022.2159765","url":null,"abstract":"<p><p>Probiotics positively influence age-related macular degeneration (ARMD) given their propensity to attenuate oxidative and inflammatory stress. We addressed the impact of probiotics on metabolic profiles, clinical indices, inflammatory and oxidative stress parameters in ARMD patients. We performed a randomized, double-blind, placebo-controlled trial analyzing 57 subjects with ARMD aged between 50 and 85 years. Subjects were randomized into two groups, and received daily for 8 weeks either probiotic capsule or placebo. Fasting blood samples were obtained at baseline and after the 8-week intervention for the determination of metabolic profiles and oxidative stress biomarkers. After the 8-week intervention, compared with the placebo, probiotic supplementation significantly increased means HDL-cholesterol (Probiotic group: +3.86±4.42 vs. Placebo group: -0.55±4.93 mg/dL, P = .001), plasma total antioxidant capacity (TAC) (Probiotic group: +77.43±168.30 vs. Placebo group: -23.12±169.22 mmol/L, P = .02) and significantly decreased malondialdehyde (MDA) levels (Probiotic group: -0.18±0.46 vs. Placebo group: +0.18±0.25 µmol/L, P = .001). There was no significant effect of probiotic administration on other metabolic profiles and clinical symptoms. Overall, an eight-week probiotic administration among ARMD patients had beneficial effects on TAC, MDA and HDL-cholesterol levels; however, it did not affect clinical signs and other metabolic profiles.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"229-241"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9267956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Changes in the immune system participate in the pathogenesis and development of infectious diseases. Previous studies have indicated immune dysregulation in patients suffering from COVID-19 and mucormycosis. Therefore, this study investigated whether interleukin-27 (IL-27) and interleukin-32 (IL-32) levels may participate in the development and outcome of COVID-19 associated mucormycosis (CAM). The blood samples were obtained from 79 patients suffering from COVID-19 and mucormycosis and 25 healthy subjects. The serum samples were isolated from the whole blood and frequencies of some immune cells were measured by a cell counter. The levels of IL-27 and IL-32 were assessed by enzyme-linked immunosorbent assay. IL-27 and IL-32 levels were significantly lower in patients with COVID-19 and mucormycosis than healthy subjects (P < .05), although there was no significant difference in IL-27 between patients with COVID-19 and CAM. IL-27 level was significantly higher in severe COVID-19 survivors than dead cases (P < .01). Patients with CAM had significant increases in NLR compared to COVID-19 patients and healthy individuals (P < .0001-0.01). NLR was significantly associated with COVID-19 outcome (P < .05). Severe COVID-19 survivors had a significant reduction in NLR compared to non-survivors (P < .05). Changes in IL-27 and IL-32 levels may contribute to the pathogenesis of CAM. IL-27 may relate to the pathogenesis and outcomes of mucormycosis in COVID-19 patients.
{"title":"Impacts of IL-27 and IL-32 in the pathogenesis and outcome of COVID-19 associated mucormycosis.","authors":"Batool Zamani, Mansooreh Momen-Heravi, Mahzad Erami, Hossein Motedayyen, Reza ArefNezhad","doi":"10.1080/15321819.2022.2164506","DOIUrl":"https://doi.org/10.1080/15321819.2022.2164506","url":null,"abstract":"<p><p>Changes in the immune system participate in the pathogenesis and development of infectious diseases. Previous studies have indicated immune dysregulation in patients suffering from COVID-19 and mucormycosis. Therefore, this study investigated whether interleukin-27 (IL-27) and interleukin-32 (IL-32) levels may participate in the development and outcome of COVID-19 associated mucormycosis (CAM). The blood samples were obtained from 79 patients suffering from COVID-19 and mucormycosis and 25 healthy subjects. The serum samples were isolated from the whole blood and frequencies of some immune cells were measured by a cell counter. The levels of IL-27 and IL-32 were assessed by enzyme-linked immunosorbent assay. IL-27 and IL-32 levels were significantly lower in patients with COVID-19 and mucormycosis than healthy subjects (P < .05), although there was no significant difference in IL-27 between patients with COVID-19 and CAM. IL-27 level was significantly higher in severe COVID-19 survivors than dead cases (P < .01). Patients with CAM had significant increases in NLR compared to COVID-19 patients and healthy individuals (P < .0001-0.01). NLR was significantly associated with COVID-19 outcome (P < .05). Severe COVID-19 survivors had a significant reduction in NLR compared to non-survivors (P < .05). Changes in IL-27 and IL-32 levels may contribute to the pathogenesis of CAM. IL-27 may relate to the pathogenesis and outcomes of mucormycosis in COVID-19 patients.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"242-255"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9272514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-04DOI: 10.1080/15321819.2023.2167521
Pascal Hishamund, Benjamin Obukowho Emikpe, Anselime Shyakaa
The status of Infectious bursal disease (IBD) in indigenous chickens and backyard poultry in Rwanda has not been previously elucidated. This cross-sectional study was to determine the seroprevalence of infectious bursal disease in indigenous chickens and to identify the associated factors. The study was been done in three districts in the Eastern province of Rwanda where blood from 364 indigenous chickens were collected. ID Screen® IBD indirect enzyme-linked immunosorbent assay (ELISA) test was used to detect IBD antibodies in these birds. 145 questionnaires were also administered to poultry farmers to obtain information on biosecurity measures and associated factors to IBD outbreaks. The study revealed 48.4% (176/364) prevalence of the chicken with IBDV antibodies with statistical significance (P < .05) among/between location and age groups. The questionnaire revealed that there were other important associated factors which included chicken scavenging for seed as a source of food (59.3% of farmers reported), absence of routine vaccination (53.8%), live chickens are purchased from the open market with no information about IBD outbreaks and vaccination (30.0%), open disposal of dead chickens suspected of IBD (58.9%). IBD virus antibodies are present in indigenous chicken in Eastern Rwanda hence further investigation to better understand the epidemiology of IBD virus in indigenous chickens is desired and more research is needed to identify the role of indigenous chickens in the spread of IBD virus in Rwanda.
{"title":"Seroprevalence and associated factors of infectious bursal disease (IBD) in indigenous chicken in eastern province in Rwanda.","authors":"Pascal Hishamund, Benjamin Obukowho Emikpe, Anselime Shyakaa","doi":"10.1080/15321819.2023.2167521","DOIUrl":"https://doi.org/10.1080/15321819.2023.2167521","url":null,"abstract":"<p><p>The status of Infectious bursal disease (IBD) in indigenous chickens and backyard poultry in Rwanda has not been previously elucidated. This cross-sectional study was to determine the seroprevalence of infectious bursal disease in indigenous chickens and to identify the associated factors. The study was been done in three districts in the Eastern province of Rwanda where blood from 364 indigenous chickens were collected. ID Screen® IBD indirect enzyme-linked immunosorbent assay (ELISA) test was used to detect IBD antibodies in these birds. 145 questionnaires were also administered to poultry farmers to obtain information on biosecurity measures and associated factors to IBD outbreaks. The study revealed 48.4% (176/364) prevalence of the chicken with IBDV antibodies with statistical significance (P < .05) among/between location and age groups. The questionnaire revealed that there were other important associated factors which included chicken scavenging for seed as a source of food (59.3% of farmers reported), absence of routine vaccination (53.8%), live chickens are purchased from the open market with no information about IBD outbreaks and vaccination (30.0%), open disposal of dead chickens suspected of IBD (58.9%). IBD virus antibodies are present in indigenous chicken in Eastern Rwanda hence further investigation to better understand the epidemiology of IBD virus in indigenous chickens is desired and more research is needed to identify the role of indigenous chickens in the spread of IBD virus in Rwanda.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"296-308"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9272997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dear Editor, The only method that is available to study the control of alternative C3/C5convertase by the complement factor H (CFH) was developed by the team of Pilar Sánchez-Corral in 2003 using sheep erythrocytes. Nonetheless, we recall that the control of alternative C3/C5-convertase activity by CFH depends on the trimolecular complex formation of C3b-CFH-Factor I (FI) that itself depend on the binding capacity of CFH to cell membranes. Meanwhile, defective interactions at CFH–heparin sites reduce the CFH activity on surface-bound C3b, while the fluid phase activity continues to prevent C3/C5-convertase formation. On the other hand, Zn2+ that ranges between 2 and 15 μM in physiology, has the capacity to inhibit cell lysis induced by activated complement when its concentrations exceed 50 μM as initially described by Gotze et al. on red cells. The most relevant comprehensive mechanism of this hemolysis inhibition was deciphered by the team of Stephen J. Perkins who are shaping an emerging view based on the capacity of zinc to induce nonphysiologically complex between C3 molecules and complement factor H (CFH). Nevertheless, all these previous reports regarding Zn/CFH interaction were limited to purified systems using biophysical methods and fluid-phase degradation assays, and no study has yet addressed this question using Pilar Sánchez-Corral assay that uses sheep erythrocytes as a non-activator surface. To study CFH interaction with Zn2+, we have used two hemolytic assays (AP50 using rabbit red cells as activator surface and Pilar Sánchez-Corral’s CFH Functional assays), which are based on the formation of hydrophilic pores through which hemoglobin is able to pass and assessed spectrophotometrically as described previously. Indeed, we have succeeded to evidence the opposite and reversible effects of Zn2+ on ACP by demonstrating that physiological and micromolar concentrations of Zn2+ exert an inhibitory action on ACP simultaneously to a slight enhancement of CFH effectiveness in a dose-dependent manner (Figure 1). By using analytical ultracentrifugation and x-ray scattering, Nan et al. (2013) explain that in the presence of excess zinc above 100 μM zinc, very large complexes of CFH and C3b with zinc precipitate out of solution, thus reducing the availability of C3b to mediate its normal ACP response as evidenced by the functional test based on the lysis of chicken erythrocytes in an agarose gel. JOURNAL OF IMMUNOASSAY AND IMMUNOCHEMISTRY 2023, VOL. 44, NO. 3, 309–312 https://doi.org/10.1080/15321819.2023.2173529
{"title":"The blocking effect of zinc on complement factor H <i>in vitro</i>: further proof by the hemolytic assay of Pilar Sánchez-Corral.","authors":"Kheir Eddine Kerboua, Saadia Lasla, Maria-Hadjer Kerboua, Kamel Djennouhat","doi":"10.1080/15321819.2023.2173529","DOIUrl":"https://doi.org/10.1080/15321819.2023.2173529","url":null,"abstract":"Dear Editor, The only method that is available to study the control of alternative C3/C5convertase by the complement factor H (CFH) was developed by the team of Pilar Sánchez-Corral in 2003 using sheep erythrocytes. Nonetheless, we recall that the control of alternative C3/C5-convertase activity by CFH depends on the trimolecular complex formation of C3b-CFH-Factor I (FI) that itself depend on the binding capacity of CFH to cell membranes. Meanwhile, defective interactions at CFH–heparin sites reduce the CFH activity on surface-bound C3b, while the fluid phase activity continues to prevent C3/C5-convertase formation. On the other hand, Zn2+ that ranges between 2 and 15 μM in physiology, has the capacity to inhibit cell lysis induced by activated complement when its concentrations exceed 50 μM as initially described by Gotze et al. on red cells. The most relevant comprehensive mechanism of this hemolysis inhibition was deciphered by the team of Stephen J. Perkins who are shaping an emerging view based on the capacity of zinc to induce nonphysiologically complex between C3 molecules and complement factor H (CFH). Nevertheless, all these previous reports regarding Zn/CFH interaction were limited to purified systems using biophysical methods and fluid-phase degradation assays, and no study has yet addressed this question using Pilar Sánchez-Corral assay that uses sheep erythrocytes as a non-activator surface. To study CFH interaction with Zn2+, we have used two hemolytic assays (AP50 using rabbit red cells as activator surface and Pilar Sánchez-Corral’s CFH Functional assays), which are based on the formation of hydrophilic pores through which hemoglobin is able to pass and assessed spectrophotometrically as described previously. Indeed, we have succeeded to evidence the opposite and reversible effects of Zn2+ on ACP by demonstrating that physiological and micromolar concentrations of Zn2+ exert an inhibitory action on ACP simultaneously to a slight enhancement of CFH effectiveness in a dose-dependent manner (Figure 1). By using analytical ultracentrifugation and x-ray scattering, Nan et al. (2013) explain that in the presence of excess zinc above 100 μM zinc, very large complexes of CFH and C3b with zinc precipitate out of solution, thus reducing the availability of C3b to mediate its normal ACP response as evidenced by the functional test based on the lysis of chicken erythrocytes in an agarose gel. JOURNAL OF IMMUNOASSAY AND IMMUNOCHEMISTRY 2023, VOL. 44, NO. 3, 309–312 https://doi.org/10.1080/15321819.2023.2173529","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"309-312"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9346884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study was designed to evaluate the immunohistochemical expression of programmed death ligand-1 (PD-L1) in tumor cells (TCs) and tumor-infiltrating immune cells (TICs) in hepatocellular carcinoma (HCC) and to correlate its expression with clinicopathological parameters. Seventy-two formalin-fixed paraffin-embedded blocks of HCC were collected. The data were collected from the patients' records. The blocks were stained with hematoxylin and eosin. Additionally, they were immunostained with PD-L1. Membranous staining was considered positive expression including the entire membrane or part of it ± cytoplasmic staining, and the percentage of total cancer cells ≥ 5% was evaluated as positive staining for TCs. The TICs were considered positive if they expressed membranous ± cytoplasmic staining of PD-L1 ≥ 1%. Of the total cases, 34.7% expressed PD-L1 positively in TCs and 15.3% expressed PD-L1 positively in TICs. Significant associations were observed between PD-L1 expression in TCs and tumor grade, capsular and/or vascular invasion, tumor stage, nodal metastasis, and the expression of PD-L1 in paracancerous tissue. The cases that positively expressed PD-L1 exhibited reduced overall survival (OS). PD-L1 was expressed in HCC TCs and TICs. Its expression in TCs was associated with higher HCC grades, advanced stages, capsular and/or vascular invasion, and nodal metastasis, and cases that expressed PD-L1 displayed reduced OS. Therefore, PD-L1 might serve as a poor prognostic indicator and a tumor immunotherapy target.
{"title":"Immunohistochemical expression of immune check point protein PDL-1 in hepatocellular carcinoma denotes its prognostic significance and association with survival.","authors":"Dina Omar Helmy, Fatma Khattab, Azza Elsayed Hegazy, Rania Mohamed Sabry","doi":"10.1080/15321819.2022.2137810","DOIUrl":"https://doi.org/10.1080/15321819.2022.2137810","url":null,"abstract":"<p><p>This study was designed to evaluate the immunohistochemical expression of programmed death ligand-1 (PD-L1) in tumor cells (TCs) and tumor-infiltrating immune cells (TICs) in hepatocellular carcinoma (HCC) and to correlate its expression with clinicopathological parameters. Seventy-two formalin-fixed paraffin-embedded blocks of HCC were collected. The data were collected from the patients' records. The blocks were stained with hematoxylin and eosin. Additionally, they were immunostained with PD-L1. Membranous staining was considered positive expression including the entire membrane or part of it ± cytoplasmic staining, and the percentage of total cancer cells ≥ 5% was evaluated as positive staining for TCs. The TICs were considered positive if they expressed membranous ± cytoplasmic staining of PD-L1 ≥ 1%. Of the total cases, 34.7% expressed PD-L1 positively in TCs and 15.3% expressed PD-L1 positively in TICs. Significant associations were observed between PD-L1 expression in TCs and tumor grade, capsular and/or vascular invasion, tumor stage, nodal metastasis, and the expression of PD-L1 in paracancerous tissue. The cases that positively expressed PD-L1 exhibited reduced overall survival (OS). PD-L1 was expressed in HCC TCs and TICs. Its expression in TCs was associated with higher HCC grades, advanced stages, capsular and/or vascular invasion, and nodal metastasis, and cases that expressed PD-L1 displayed reduced OS. Therefore, PD-L1 might serve as a poor prognostic indicator and a tumor immunotherapy target.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"213-228"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9320428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-04DOI: 10.1080/15321819.2023.2189471
Heba A S Bazid, Alaa Marae, Nermin Tayel, Etab Serag, Hadeer Selim, Mohammed I Mostafa, Eman Abd El Gayed
Psoriasis is characterized by cutaneous hyperproliferation, secondary to immune system dysregulation. Vitamin A regulates the immune response and sustains epithelial tissue hemostasis. The CYP1A1 gene, has many biological actions, including vitamin A metabolism. To evaluate CYP1A1 gene polymorphism and serum vitamin A level in patients with psoriasis vulgaris, a case-control study involving two groups was conducted: group 1 (45 patients with psoriasis vulgaris) served as the cased group and group 2 (45 healthy participants who were sex and age matched) acted as the control group. CYP1A1 (rs1048943) gene polymorphism and vitamin A serum level were assessed by TaqMan allelic discrimination (PCR) and ELISA, respectively. AG genotype was present only in cases (22.2%), while AA genotype was present in all controls (P=.001). Vitamin A levels were lower in cases than in controls (32.0 ± 7.41 vs. 46.2 ± 15.7 μg/ml, respectively) (P<.001). AG genotype was associated with a lower vitamin A level (P=.001). The detected genotype difference between psoriasis patients and controls, which was associated with a lower serum vitamin A level and was also lower in more severe cases, suggests a role of the CYP1A1 gene and vitamin A in disease pathogenesis and prognosis.
银屑病的特点是皮肤增生,继发于免疫系统失调。维生素A调节免疫反应,维持上皮组织止血。CYP1A1基因具有多种生物作用,包括维生素A代谢。为评价寻常型银屑病患者CYP1A1基因多态性及血清维生素A水平,采用两组病例对照研究:1组(45例寻常型银屑病患者)为病例组,2组(45例性别、年龄相匹配的健康受试者)为对照组。采用TaqMan等位基因鉴别(PCR)和ELISA检测CYP1A1 (rs1048943)基因多态性和血清维生素A水平。AG基因型仅在病例中存在(22.2%),而AA基因型在所有对照组中存在(P=.001)。患者的维生素A水平低于对照组(分别为32.0±7.41 vs. 46.2±15.7 μg/ml) (PP= 0.001)。银屑病患者与对照组之间检测到的基因型差异与较低的血清维生素a水平有关,在更严重的病例中也较低,提示CYP1A1基因和维生素a在疾病发病机制和预后中的作用。
{"title":"Assessment of cytochrome P450 1A1 gene polymorphism and vitamin A serum level in psoriasis vulgaris.","authors":"Heba A S Bazid, Alaa Marae, Nermin Tayel, Etab Serag, Hadeer Selim, Mohammed I Mostafa, Eman Abd El Gayed","doi":"10.1080/15321819.2023.2189471","DOIUrl":"https://doi.org/10.1080/15321819.2023.2189471","url":null,"abstract":"<p><p>Psoriasis is characterized by cutaneous hyperproliferation, secondary to immune system dysregulation. Vitamin A regulates the immune response and sustains epithelial tissue hemostasis. The CYP1A1 gene, has many biological actions, including vitamin A metabolism. To evaluate CYP1A1 gene polymorphism and serum vitamin A level in patients with psoriasis vulgaris, a case-control study involving two groups was conducted: group 1 (45 patients with psoriasis vulgaris) served as the cased group and group 2 (45 healthy participants who were sex and age matched) acted as the control group. CYP1A1 (rs1048943) gene polymorphism and vitamin A serum level were assessed by TaqMan allelic discrimination (PCR) and ELISA, respectively. AG genotype was present only in cases (22.2%), while AA genotype was present in all controls (<i>P</i>=.001). Vitamin A levels were lower in cases than in controls (32.0 ± 7.41 vs. 46.2 ± 15.7 μg/ml, respectively) (<i>P</i><.001). AG genotype was associated with a lower vitamin A level (<i>P</i>=.001). The detected genotype difference between psoriasis patients and controls, which was associated with a lower serum vitamin A level and was also lower in more severe cases, suggests a role of the CYP1A1 gene and vitamin A in disease pathogenesis and prognosis.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"269-282"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9322531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-04DOI: 10.1080/15321819.2023.2168557
Wafaa Ahmed Shehata, Mostafa Ahmed Hammam, Aya Abdo, Nermin Tayel, Shimaa Abdelsattar
Alopecia areata (AA) is a disorder with several etiologies. The evidence suggests that the absolute copy number of mitochondrial deoxyribonucleic acid (mtDNA), as well as proportion of mutated mtDNA copies, determines disease onset. This study aims to quantify the relative index of the mtDNA copy number in patients with AA and healthy controls and correlate the results with the existing clinical information. This case-control study included 50 patients with AA and 50 age- and sex-coordinated healthy persons as controls. The severity of AA was weighed using the Severity of Alopecia Tool and Kavak's classification. The relative index of the mtDNA copy number was measured by real-time qPCR. Significant statistical difference was observed between cases and controls regarding mean mtDNA copy number, p < .001. There was significant positive correlation with SALT score (p = 0.001). A cutoff value of >1.619 N/µL could significantly diagnose AA cases (p < .001), and a cutoff value of > 1.36 N/µL could discriminate mild AA cases from those with moderate AA (p = 0.007). The relative index of mtDNA copy number is significantly elevated in AA cases and could be helpful in diagnosing and evaluating AA severity.
斑秃(AA)是一种有多种病因的疾病。有证据表明,线粒体脱氧核糖核酸(mtDNA)的绝对拷贝数以及突变mtDNA拷贝的比例决定了疾病的发生。本研究旨在量化AA患者和健康对照者mtDNA拷贝数的相对指标,并将结果与现有临床信息相关联。本病例对照研究包括50例AA患者和50例年龄和性别一致的健康人作为对照。AA的严重程度采用脱发严重程度评分法和Kavak分级法进行加权。实时荧光定量pcr检测mtDNA拷贝数的相对指标。病例与对照组mtDNA拷贝数差异有统计学意义(p p = 0.001)。临界值>1.619 N/µL可显著诊断AA (p = 1.36 N/µL可区分轻度AA和中度AA, p = 0.007)。mtDNA拷贝数相对指标在AA患者中显著升高,可用于诊断和评价AA的严重程度。
{"title":"Mitochondrial DNA copy number as a diagnostic marker and indicator of degree of severity in alopecia areata.","authors":"Wafaa Ahmed Shehata, Mostafa Ahmed Hammam, Aya Abdo, Nermin Tayel, Shimaa Abdelsattar","doi":"10.1080/15321819.2023.2168557","DOIUrl":"https://doi.org/10.1080/15321819.2023.2168557","url":null,"abstract":"<p><p>Alopecia areata (AA) is a disorder with several etiologies. The evidence suggests that the absolute copy number of mitochondrial deoxyribonucleic acid (mtDNA), as well as proportion of mutated mtDNA copies, determines disease onset. This study aims to quantify the relative index of the mtDNA copy number in patients with AA and healthy controls and correlate the results with the existing clinical information. This case-control study included 50 patients with AA and 50 age- and sex-coordinated healthy persons as controls. The severity of AA was weighed using the Severity of Alopecia Tool and Kavak's classification. The relative index of the mtDNA copy number was measured by real-time qPCR. Significant statistical difference was observed between cases and controls regarding mean mtDNA copy number, <i>p </i>< .001. There was significant positive correlation with SALT score (<i>p</i> = 0.001). A cutoff value of >1.619 N/µL could significantly diagnose AA cases (<i>p </i>< .001), and a cutoff value of > 1.36 N/µL could discriminate mild AA cases from those with moderate AA (<i>p</i> = 0.007). The relative index of mtDNA copy number is significantly elevated in AA cases and could be helpful in diagnosing and evaluating AA severity.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":"44 3","pages":"256-268"},"PeriodicalIF":0.0,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9260356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}